Bridged MGL Modulators for Selective Endocannabinoid Elevation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and disorders associated with monoacylglycerol lipase (MGL) activity, such as neuroinflammation, neurodegenerative diseases, and mood disorders, often have side effects due to the broad modulation of cannabinoid receptors, and there is a need for targeted MGL modulation to minimize these effects.
Innovation Solution
Development of bridged chemical entities that act as MGL modulators, including inhibitors, to specifically enhance 2-arachidonoylglycerol (2-AG) levels and attenuate proinflammatory cascades, thereby treating a range of diseases without the full spectrum of neurobehavioral effects seen with CB1 agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional approaches (dietary changes, exercise, NSAIDs) are used to manage osteoarthritis, then symptom relief may be achieved, but they fail to address the underlying cause (accumulation of lipid metabolites) and have limited efficacy or significant side effects
Solution Approach 1:
The patent introduces MLAs (monoacylglycerol lipase modulators) as intermediary substances that specifically target and modulate monoacylglycerol lipase activity. These modulators act as mediators between the accumulated lipid metabolites (2-AG and PEA) and the cannabinoid receptors, enhancing the body's natural endocannabinoid system to address osteoarthritis pain and inflammation without the harmful side effects of NSAIDs
Solution Approach 2:
The patent leverages the body's own endocannabinoid system and naturally produced lipid metabolites (2-AG and PEA) to treat osteoarthritis. By modulating ML activity, the treatment enhances the body's self-regulatory mechanisms, allowing endogenous cannabinoids to perform their pain-relieving and anti-inflammatory functions without requiring external substances with side effects
2Reliability
If ML activity is modulated to increase endogenous cannabinoids, then pain relief and anti-inflammatory effects are enhanced, but the mechanism is not yet fully understood or optimized
Solution Approach 1:
The patent performs preliminary identification and characterization of ML modulators and their effects on endocannabinoid levels before full mechanism elucidation. By pre-clinically validating the approach of ML modulation to increase 2-AG and PEA levels, the patent establishes a foundation for understanding the mechanism while already demonstrating therapeutic potential
Solution Approach 2:
The patent implements a feedback mechanism where ML modulators are administered to increase endogenous cannabinoid levels, which then exert pain-relieving and anti-inflammatory effects, and the response is monitored to optimize treatment. The patent describes measuring endocannabinoid levels and correlating them with therapeutic outcomes to refine the mechanism understanding
Data Source
AI summary
Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. and; wherein R2, R3 R4, R5 and R6 are defined herein.